Vivimed Labs Limited has officially postponed its board meeting that was scheduled to take place on February 13, 2026, for the approval of its third quarter FY 2026 financial results. The pharmaceutical company communicated this development to both the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) through a formal notice dated February 11, 2026.

Meeting Postponement Details

The company's communication, signed by Company Secretary Yugandhar Kopparthi, informed the stock exchanges about the postponement without specifying the reasons for the delay. The original meeting was intended to approve the financial results for the third quarter of FY 2026.

Regulatory Compliance and Trading Window

Vivimed Labs has assured that it will intimate the revised date for the board meeting to the stock exchanges in due course. In compliance with regulatory requirements, the company has confirmed that the trading window for dealing in its securities will remain closed for designated persons until 48 hours after the declaration of the financial results following the rescheduled meeting.

Stock Exchange Information

The company trades on both major Indian stock exchanges with BSE code 532660 and NSE symbol VIVIMEDLAB. The formal communication was addressed to both exchanges as part of the mandatory disclosure requirements for listed companies.

Company Background

Vivimed Labs Limited operates with its registered office located at Kolhar Industrial Area, Bidar, Karnataka, and maintains its corporate office in Hyderabad, Telangana. The company is incorporated under CIN L02411KA1988PLC009465 and has been a listed entity on Indian stock exchanges.

Vivimed Labs Limited has secured significant legal relief as the Telangana High Court granted an interim stay on all Central Bureau of Investigation proceedings following search and seizure operations conducted at the pharmaceutical company's premises. The development comes after the company approached the High Court challenging the CBI actions initiated based on a State Bank of India complaint.

CBI Search and Seizure Operations

The Central Bureau of Investigation conducted search and seizure operations at Vivimed Labs' premises on 20th January, 2026. The operations were carried out by CBI's Banking Securities Fraud Branch from Bengaluru and New Delhi based on a complaint filed by State Bank of India's IFB branch in Hyderabad.

High Court Interim Relief

Vivimed Labs approached the High Court for the State of Telangana at Hyderabad seeking relief from the CBI proceedings. On 6th February, 2026, Justice Nagesh Bheemapaka granted comprehensive interim relief to the company in Writ Petition No. 1843 of 2026.

The High Court's interim order provides significant protection to Vivimed Labs by staying all further proceedings pursuant to the search and seizure operations. The court has restrained the CBI from taking any coercive steps against the company, its directors, and other stakeholders based on the search operations conducted on 20th January, 2026.

Legal Arguments and Court's Reasoning

Senior Counsel Avinash Desai, representing Vivimed Labs, argued that the search and seizure operations were based on SBI's classification of the company's account as 'fraud'. The counsel contended that this fraud declaration had been previously suspended by the court in an earlier petition (W.P.No.24697 of 2025), making the CBI's reliance on such classification inappropriate.

The High Court accepted these arguments and noted that since the fraud declaration was under suspension, the CBI should not have proceeded with coercive actions based on that classification.

Comprehensive Stay Order

The interim stay order encompasses multiple aspects of protection for Vivimed Labs. The court has restrained the CBI from taking any coercive steps based on both the search and seizure operations and SBI's complaint or fraud declaration. This comprehensive relief covers all proceedings until further orders from the High Court.

The case is scheduled for next hearing on 6th March, 2026, when the court will further examine the matter and determine the future course of action.